NuVasive, Inc.  

(Public, NASDAQ:NUVA)   Watch this stock  
Find more results for nuvasive
63.50
+0.09 (0.14%)
Dec 2 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 63.00 - 64.15
52 week 36.81 - 69.50
Open 63.37
Vol / Avg. 655,491.00/946,088.00
Mkt cap 3.12B
P/E 80.59
Div/yield     -
EPS 0.79
Shares 50.35M
Beta 0.97
Inst. own 106%
Feb 9, 2017
Q4 2016 NuVasive Inc Earnings Release (Estimated) - 9:30AM EST - Add to calendar
Nov 29, 2016
NuVasive Inc at Piper Jaffray Healthcare Conference - Webcast
Oct 25, 2016
Q3 2016 NuVasive Inc Earnings Call - Webcast
Oct 25, 2016
Q3 2016 NuVasive Inc Earnings Release
Sep 13, 2016
NuVasive Inc at Morgan Stanley Global Healthcare Conference
Sep 7, 2016
NuVasive Inc at Wells Fargo Securities Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '16) 2015
Net profit margin 1.46% 8.05%
Operating margin 8.83% 17.15%
EBITD margin - 21.17%
Return on average assets 0.86% 4.94%
Return on average equity 2.22% 9.81%
Employees 1,600 -
CDP Score - -

Address

7475 Lusk Blvd
SAN DIEGO, CA 92121-5707
United States - Map
+1-858-9091800 (Phone)
+1-800-4759134 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Nuvasive, Inc. is a medical device company in the spine market. The Company focuses on developing minimally-disruptive surgical products and procedurally-integrated solutions for the spine. The Company offers two product lines: spine surgery products and biologics. The Company's spine surgery products line offerings include thoracolumbar product offerings, cervical product offerings, Intra-Operative Monitoring (IOM) services and disposables, which are used to enable access to the spine and to perform restorative and fusion procedures in a minimally disruptive fashion. The Company's biologics product line offerings includes allograft (donated human tissue), FormaGraft (a collagen synthetic product), Osteocel Plus and Osteocel Pro (each an allograft cellular matrix containing viable mesenchymal stem cells (MSCs)), and AttraX (a synthetic bone graft material), all of which are used to aid the spinal fusion or bone healing process.

Officers and directors

Gregory T. Lucier Chairman of the Board, Chief Executive Officer
Age: 51
Bio & Compensation  - Reuters
Jason M. Hannon President, Chief Operating Officer
Age: 44
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Matthew W. Link President - U.S. Commercial
Age: 41
Bio & Compensation  - Reuters
Patrick W. G. Miles Vice Chairman of the Board
Age: 50
Bio & Compensation  - Reuters
Quentin S. Blackford Chief Financial Officer, Executive Vice President
Age: 37
Bio & Compensation  - Reuters
Joan Stafslien Executive Vice President, General Counsel, Corporate Secretary
Bio & Compensation  - Reuters
Carol A. Cox Executive Vice President - External Affairs and Corporate Marketing
Age: 51
Bio & Compensation  - Reuters
Jason D. Hanson Executive Vice President - Strategy, Corporate Development and General Counsel
Age: 47
Bio & Compensation  - Reuters
Peter Michael Leddy Ph.D. Executive Vice President - Corporate Integrity and Global Human Resources
Age: 53
Bio & Compensation  - Reuters
Jack R. Blair Independent Director
Age: 73
Bio & Compensation  - Reuters